Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
Labour leader says the UK "should not be afraid of debt or borrowing" as he urges the government to "stop dithering" and start investing.
A fundraising page for a Westminster terror attack victim has been taken over by JustGiving amid fears it was set up by a fraudster.
ITV News rounds up the best pictures of the day as campaigners make a final stand before Theresa May triggers Brexit on Wednesday.